H eart failure is a costly and deadly disease affecting >23 million patients worldwide. 1 At the core of the pathophysiology of heart failure is the inability of the adult mammalian heart to regenerate after myocardial loss, which is in marked contrast to terelost fish, 2-4 urodele amphibians, 5-8 and mammalian neonates. 9, 10 In mammals, most of the cardiomyocytes are permanently withdrawn from cell cycle soon after birth, and despite extensive efforts to identify regulators of cardiomyocyte cell cycle in mammals, [11] [12] [13] [14] [15] the signaling cascades that activate/repress cell cycle in mammalian cardiomyocytes remain unclear.
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Hippo signaling, which is an evolutionary conserved pathway that regulates cell proliferation, survival, differentiation, and organ size 16 has received significant attention in the field of regenerative medicine recently. On activation of the Hippo pathway in mice, Ste20 family kinases MST1/2 interact with scaffolding protein WW45 to phosphorylate and activate LATS1/2 kinase which in turn forms a complex with its cofactor MOB1 to phosphorylate and inactivate yes-associated protein (YAP) and TAZ, the downstream transcriptional regulators of the signaling pathway. In contrast, when the Hippo pathway is inactivated, YAP and PDZ-binding motif (TAZ) accumulate in the nucleus to interact with transcriptional enhancer activator (TEA) domain family of proteins, along with other proteins such as, small mothers against decapentaplegic (SMADs), octamer-binding transcription factor 4 (OCT4), or angiomotin (AMOT), to promote gene expression for cellular proliferation and organ growth. 17 Recently, several studies have uncovered the importance of Hippo signaling pathway in heart development and regeneration. Knock-down of an upstream effector of Hippo cascade, Salv (WW45), 18 and also forced expression of a constitutively active form of YAP (S127A in human and S112A in mouse) in the fetal heart, promoted cadiomyocyte proliferation and thickening of myocardial wall. 19, 20 In contrast, specific deletion of Yap in cardiomyocytes resulted in cardiac hypoplasia and lethality, 19, 20 demonstrating the necessity of Hippo signaling pathway in cardiomyocyte proliferation during embryonic development. The significance of Hippo pathway in postnatal cardiac homeostasis and repair has also been demonstrated where cardiomyocyte-specific knockout of Yap or Taz results in lethal cardiomyopathy, 13 whereas expression of YAPS112A in mouse heart stimulated postnatal reactivation of cardiomyocyte proliferation and enhanced cardiac function in mice after myocardial infarction (MI) injury. 13, 21 In addition, deletion of Salv or Lats1/2 in postnatal mice with postnatal day 7 apex resection or adult with myocardial infarction promotes heart regeneration. 22 These results indicate that Hippo signaling is a potentially important target for promoting myocardial regeneration.
Despite these results, downstream mediators of Hippo signaling pathway that regulate cardiomyocyte proliferation are not fully understood. Previous studies using constitutively active YAP revealed that the Hippo-YAP pathway augments insulinlike growth factor signaling, which in turn induces activation of the phosphoinositide 3 kinase-AKT (PI3K-AKT) pathway. 19 Phosphorylated AKT inactivates glycogen synthase kinase-3β (GSK-3β) by increasing its phosphorylation, leading to the stabilization of β-catenin, which in turn is required for Yap-mediated proliferation. This pathway has been well studied in a variety of disease models, such as cancer and diabetes mellitus. [23] [24] [25] [26] [27] In this issue, Lin et al 28 reported the identification of one of the direct transcriptional targets of YAP, an isoform of PI3K catalytic subunit PIK3CB, that regulates cardiomyocyte proliferation as a downstream mediator of Hippo-YAP signaling. ChIP-seq analysis combined with 3 different systems-(1) overexpression of YAP in cardiomyocyte-like HL cells, (2) overexpression of YAP in rat neonatal ventricular cardiomyocytes, and (3) cardiomyocyte-specific Yap homozygous knockout, identified YAPbinding sites which are significantly enriched in genes related to heart development. Among candidate YAP target genes, the authors focused on Pik3cb, the function of which has not been understood thus far. A YAP-bound region containing conserved TEA domain motif, was in the first-intron of Pik3cb, through which YAP-TEA domain activates transcription of Pik3cb. Importantly, the authors showed that forced-expression of PIK3CB is sufficient to activate PI3K-AKT pathway, and hence to regulate cardiomyocyte proliferation. Adenoviral transfection of Pik3cb to neonatal ventricular cardiomyocytes, and in vivo overexpression of YAP driven by cTNT promoter in neonatal cardiomyocyte using AAV9, both significantly activated AKT by triggering the phosphorylation of AKT, and induced cardiomyocyte proliferation assessed by BrdU uptake and immune staining with phosphorylated histone H3 antibody. Mice with cardiomyocyte-specific Yap deletion showed reduced phosphorylated AKT but not total AKT, which is consistent with the findings in cancer cell lines 29 and neonatal cardiomyocytes. 19 Moreover, Lin et al 28 showed that Pik3cb is necessary for Yap-mediated activation of AKT and cardiomyocyte proliferation. AAV9-mediated overexpression of YAP together with scrambled control or specific shRNA targeting Pik3cb showed that while YAP overexpression (with scrambled Pik3cb shRNA) promoted cardiomyocyte proliferation as previously described, 13, 19, 20 addition of Pik3cb shRNA resulted in a diminished effect of YAP overexpression on AKT phosphorylation and cardiomyocyte proliferation. Although these are convincing results, using a Pik3cb knockout model would eliminate the potential off-target effects of shRNA. Finally, the authors show that AAV9-mediated overexpression of PIK3CB in the cardiomyocyte-specific Yap knockout mice induced cardiomyocyte proliferation, improved contractile function, and attenuated cardiomyocyte hypertrophy to an extent, demonstrating that Pik3cb can partially rescue the Yap knockout phenotype in cardiomyocytes. In summary, Hippo-YAP-mediated activation of PI3K-AKT pathway, along with cardiomyocyte growth, is at least in part mediated by direct transcriptional activation of Pik3cb by Hippo-signaling mediator YAP/TEA domain complex (Figure) .
Despite these important findings, some questions remain. For example, much of the terminal effect on cell cycle is attributed to p27; however, the mechanism of regulation of p27 or the effect on other cyclin-dependent kinase inhibitors has not been fully examined. In addition, in the loss of function studies both decreased proliferation and survival are noted. However, the isolated effects on cell survival and proliferation are not clearly dissected, although admittedly this may be a difficult task. Finally, it would be important for future studies to examine upstream regulators of Hippo-YAP pathway, and how this pathway is regulated in the postnatal heart. Nevertheless, this report demonstrates that Pik3cb is an important link between Hippo-YAP and PI3K-AKT pathways, and brings us a step closer to an understanding of molecular mechanism regulating cardiomyocyte growth and proliferation (Figure) .
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Figure.
Hippo and PI3K-AKT signaling pathways stimulate the cardiomyocyte proliferation. Pik3cb is a gene encoding for the catalytic subunit p110 of the Class IA PI3K. Lin et al 28 found that Pik3cb is a direct target of YAP which links Hippo and PI3K-AKT signaling pathways to stimulate cardiomyocyte proliferation.
